
==== Front
Cancer Gene Ther
Cancer Gene Ther
Cancer Gene Therapy
0929-1903
1476-5500
Nature Publishing Group US New York

38409585
747
10.1038/s41417-024-00747-x
Review Article
Recent progress of CDK4/6 inhibitors’ current practice in breast cancer
http://orcid.org/0009-0007-0235-4506
Wang Xueqing 1
Zhao Shanshan 1
Xin Qinghan 2
Zhang Yunkun 3
http://orcid.org/0000-0003-2600-9700
Wang Kainan 854624115@qq.com

1
Li Man man_li@dmu.edu.cn

1
1 https://ror.org/04c8eg608 grid.411971.b 0000 0000 9558 1426 Department of Oncology, the Second Hospital of Dalian Medical University, Dalian, China
2 https://ror.org/01n6v0a11 grid.452337.4 0000 0004 0644 5246 Department of Breast Surgery, Dalian Municipal Central Hospital, Dalian, China
3 https://ror.org/04c8eg608 grid.411971.b 0000 0000 9558 1426 Department of Pathology, the Second Hospital of Dalian Medical University, Dalian, China
26 2 2024
26 2 2024
2024
31 9 12831291
20 12 2023
6 2 2024
8 2 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Dysregulated cellular proliferation represents a hallmark feature across all cancers. Aberrant activation of the cyclin-dependent kinase 4 and 6 (CDK4/6) pathway, independent of mitogenic signaling, engenders uncontrolled breast cancer cell proliferation. Consequently, the advent of CDK4/6 inhibition has constituted a pivotal milestone in the realm of targeted breast cancer therapy. The combination of CDK4/6 inhibitors (CDK4/6i) with endocrine therapy (ET) has emerged as the foremost therapeutic modality for patients afflicted with hormone receptor-positive (HR + )/HER2-negative (HER2-) advanced breast cancer. At present, the Food and Drug Administration (FDA) has sanctioned various CDK4/6i for employment as the primary treatment regimen in HR + /HER2- breast cancer. This therapeutic approach has demonstrated a substantial extension of progression-free survival (PFS), often amounting to several months, when administered alongside endocrine therapy. Within this comprehensive review, we systematically evaluate the utilization strategies of CDK4/6i across various subpopulations of breast cancer and explore potential therapeutic avenues following disease progression during application of CDK4/6i therapy.

Subject terms

Targeted therapies
Breast cancer
Liaoning Province Science and Technology Plan Joint Fund Project - Doctoral Startup FundDalian Medical University Interdisciplinary Research Cooperation Project Team Funding (JCHZ2023009)issue-copyright-statement© Springer Nature America, Inc. 2024
==== Body
pmcIntroduction

Breast cancer ranks as the most common cancer among women globally, accounting for 31% of all female cancers. It stands as the second leading cause of cancer-related fatalities in women [1, 2]. Within the spectrum of breast cancer subtypes, HR+ luminal-like tumors, including luminal A and B, represent the most prevalent category, encompassing 60–70% of all cases. For these tumors, ET serves as the primary first-line treatment in cases of advanced or metastatic breast cancer (MBC). However, the development of ET resistance is an inevitable challenge. Therefore, CDK4/6i have recently emerged as a clinically significant and well-tolerated therapeutic option for patients with MBC.

In estrogen receptor (ER)-positive breast cancer, activation of the ER signaling pathway upregulates the ER-cyclin D-CDK4/6 pathway. Cyclin-CDKs pathway plays a pivotal role in cell-cycle regulation [3]. When bound and activated by cyclin D, CDK4/6 phosphorylates the retinoblastoma protein (Rb), leading to the release of the transcription factor E2F. This promotes the transcription of genes related to the cell cycle, driving the transition of cells from the G1 phase to the S phase [4–8]. Therefore, the inhibition of both CDK4/6 and ER have shown clinical efficacy in ER+ advanced breast cancer [9]. Currently, the USA FDA has approved three CDK4/6i: Palbociclib (Pfizer), Abemaciclib (Eli Lilly), and Ribociclib (Novartis). Furthermore, the China FDA has approved Dalpiciclib (Herngri) for the first- and second-line treatment of HR + /HER2- advanced breast cancer [10]. Considering the effectiveness of CDK4/6i in HR + /HER2- MBC treatment, these drugs are now under investigation in various breast cancer subtypes and different clinical scenarios. For instance, several preclinical studies have indicated that CDK4/6i can boost tumor cell immunogenicity, leading to the exploration of CDK4/6i and Immune checkpoint inhibitor (ICI) combinations [11, 12]. In this review, we compile the most recent preclinical and clinical evidence concerning the application of CDK4/6i in breast cancer and elaborate on the treatment strategies, and advantages of these agents for different patient populations.

CDK4/6i combined with ET in HR + /HER2- advanced breast cancer

ET was the cornerstone of treatment for HR + /HER2-MBC. In the realm of HR + /HER2- breast cancer treatment, one of the most significant advancements in recent decades is the emergence of CDK4/6i (Table 1), which have proven superior to ET alone when combined with it in the majority of patients, underscoring their pivotal role [8, 13–15].Table 1 Summary of clinical trials evaluating CDK4/6 inhibitors in hormone receptor-positive and HER2-negative metastatic breast cancer.

Trial	Phase	N	Treatments	Primary endpoint Results	
PALOMA-2 (NCT01740427)	III	666	Letrozole+Palbociclib vs Placebo	PFS 24.8 vs 14.5 months (HR = 0.58, 95% CI: 0.46–0.72)	
MONALEESA-2 (NCT01958021)	III	668	Letrozole+Ribociclib vs Placebo	PFS 25.3 vs 16.0 months (HR = 0.568, 95% CI: 0.457–0.704)	
MONARCH-3 (NCT02246621)	III	493	NSAI+Abemaciclib vs Placebo	PFS 28.18 vs 14.76 months (HR = 0.540, 95% CI: 0.418–0.698)	
MONALEESA-7 (NCT02278120)	III	672	NSAI/Tamoxifen+Ribociclib+goserelin vs Placebo	PFS 23.8 vs 13.0 months (HR = 0.55, 95% CI: 0.44–0.69)	
DAWNA-2 (NCT03966898)	III	456	NSAI+Dalpiciclib vs Placebo	PFS 30.6 vs 18.2 months (HR = 0.51, 95% CI: 0.38–0.69)	
MONALEESA-3 (NCT02422615)	III	726	Fulvestrant+Ribociclib vs Placebo	PFS in patients receiving first-line treatment 33.6 vs 19.2 months (HR = 0.55, 95% CI: 0.42–0.72)	
FLIPPER (NCT02690480)	II	189	Fulvestrant+Palbociclib vs Placebo	mPFS 31.8 vs 22.0 months (HR = 0.55, 95% CI: 0.34–0.78)	
PARSIFAL (NCT02491983)	II	486	Palbociclib+Fulvestrant vs Letrozole	PFS 27.9 vs 32.8 months (HR = 1.13, 95% CI: 0.89–1.45)	
MONARCH-2 (NCT02107703)	III	669	Fulvestrant+Abemaciclib vs Placebo	PFS 16.4 vs 9.3 months (HR = 0.553, 95% CI: 0.449–0.681)	
MONARCH plus (NCT02763566)	III	207	NSAI+Abemaciclib+ vs Placebo	PFS NR vs 14.7 months (HR = 0.499, 95% CI: 0.346–0.719)	
104	Fulvestrant+Abemaciclib vs Placebo	PFS 11.5 vs 5.6 months (HR = 0.376, 95% CI: 0.240–0.588)	
PALOMA-3 (NCT01942135)	III	105	Fulvestrant+Palbociclib vs Placebo	PFS in premenopausal women age ≤50 years 9.5 vs 5.6 months (HR = 0.50, 95% CI: 0.29–0.87)	
LEONARDA-1 (NCT05054751)	III	275	Fulvestrant+Lerociclib vs Placebo	PFS 11.07 vs 5.49 months (HR = 0.458, 95% CI: 0.317–0.661)	
MAINTAIN (NCT02632045)	II	119	Fulvestrant/Exemestane+Ribociclib vs Placebo	PFS 5.29 vs 2.76 months (HR = 0.57, 95% CI: 0.39–0.85)	
BioPER (NCT03184090)	II	33	Palbociclib+ET of physician’s choice	CBR 34.4% (95% CI: 18.6–53.2); 13.0% of tumors (95% CI: 5.2–27.5) showed loss of Rb protein expression	
RIGHT (NCT03839823)	II	222	Ribociclib+goserelin+NSAI vs chemotherapy	PFS 24.0 vs 12.3 months (HR = 0.54, 95% CI: 0.36–0.79)	
PFS progression-free survival, mPFS median progression-free survival, NSAI Nonsteroidal aromatase inhibitors, CBR clinical benefit rate, ET endocrine therapy, HR hazard ratio, CI confidence interval.

Application in Endocrine-sensitive population

In clinical practice, “endocrine-sensitive population” can be defined as follows: (1) Endocrine-sensitive patients experiencing ET, denoting disease relapse after finishing adjuvant ET more than one year; (2) Endocrine-naive patients, encompassing individuals with recurrent advanced breast cancer who have not previously undergone ET or received adjuvant ET following radical surgery [16, 17]. The PALOMA-2 (77.7% of endocrine-sensitive population), MONALEESA-2 (98% of endocrine-sensitive population), and MONARCH-3 (100% of endocrine-sensitive population) trials assessed the clinical impact of three CDK4/6i—Palbociclib, Ribociclib, and Abemaciclib—in combination with aromatase inhibitor (AI). All of them exhibited significant improvements in PFS and objective response rate (ORR) for postmenopausal women with HR + /HER2- advanced breast cancer, compared to AI monotherapy [2, 18–20]. As for premenopausal women, MONALEESA-7 trial showed that ribociclib plus AI + goserelin also had a superior clinical benefit [21]. The positive PFS and overall survival (OS) results further strengthen AI’s role as a partner in first-line treatment of CDK4/6i [22, 23]. In September 2022, the DAWNA-2 trial released fresh findings at the European Society for Medical Oncology (ESMO), comparing Dalpiciclib plus AI with placebo for endocrine-sensitive HR + /HER2- advanced breast cancer. All patients can benefit from this combination therapy, regardless of their menopausal status. The study reported a median PFS (mPFS) exceeding 30 months, along with a substantial 49% reduction in the risk of disease progression or mortality. Notably, this represents a new PFS and ORR record for the combination of CDK4/6i and AI in the first-line treatment of advanced HR + /HER2- breast cancer, further solidifying its role as the first-line therapy for endocrine-sensitive patients with HR + /HER2- advanced breast cancer [24].

The MONALEESA-3 study (51% of endocrine-sensitive population) recommends Fulvestrant as another partner for CDK4/6i in the treatment of HR + /HER2- advanced breast cancer. Results indicated significant improvements in both PFS (ribociclib vs placebo group: 33.6 vs 19.2 months) and median OS (mOS) (mOS in the ribociclib group was not reached (NR), 95% CI 59.9-NR months; mOS in placebo group: 51.8 months, 95% CI 40.4-57.6 months) [25–28]. Additionally, the GEICAM/2014-12 study (FLIPPER) presented at the 2020 ESMO also focused on evaluating palbociclib in combination with fulvestrant as a first-line treatment for postmenopausal patients with endocrine-sensitive advanced breast cancer. The study demonstrated that this combination significantly improved PFS (palbociclib vs placebo group: 31.8 vs 22.0 months) and ORR (palbociclib vs placebo group: 68.3% vs 42.2%), further supporting its effectiveness in HR + /HER2- advanced breast cancer patients [29]. Additionally, the study’s patient-reported outcomes (PROs) indicated that health-related quality of life (HRQoL) was well-maintained, suggesting a favorable balance between therapeutic benefits and potential toxicities [30].

Recent research has focused on selecting the most effective endocrine partner for CDK4/6i in postmenopausal women with endocrine-sensitive, HR + /HER2- advanced breast cancer. The PARSIFAL trial, as the first head-to-head comparative trial, examined the use of palbociclib with either fulvestrant or letrozole in these patients. While the study demonstrated the favorable safety profiles of both palbociclib combinations, it did not show a significant difference in PFS (fulvestrant-palbociclib vs letrozole-palbociclib group: 27.9 vs 32.8 months; HR = 1.13; 95% CI, 0.89-1.45; P = 0.32) or other key outcomes (3-year OS, ORR, and clinical benefit rate, CBR) [31, 32].

In summary, CDK4/6i combinations stand as the primary choice for first-line endocrine therapy in endocrine-sensitive HR + /HER2- advanced breast cancer. The choice between combining CDK4/6i with AI and fulvestrant in the first-line setting remains a subject of ongoing research. Currently, the body of evidence supporting CDK4/6i combined with AI as a first-line treatment surpasses that for fulvestrant. In clinical practice, a personalized and comprehensive treatment strategy should consider factors such as patients’ prior adjuvant endocrine therapy, economic considerations, safety profiles, and the potential need for genetic testing.

Application in Endocrine-resistant population

Various clinical guidelines provide similar recommendations for the current approach to treating endocrine-resistant breast cancer. Endocrine resistance refers to resistance to current drugs, not necessarily future ones. Hence, even patients with endocrine resistance can rechallenge with endocrine therapy. Among the numerous endocrine treatment options, CDK4/6i are unquestionably essential.

In MONARCH-2, a phase III trial, patients of HR + /HER2- advanced breast cancer (including 24.9% patients with primary endocrine resistance) received fulvestrant plus abemaciclib or a placebo. Abemaciclib increased mPFS from 7.9 to 16.3 months and mOS from 31.5 to 38.7 months. However, the survival benefit wasn’t statistically significant in the primary resistance group due to the small sample [33]. The evidence supporting CDK4/6i for endocrine-resistant population is limited due to the lack of data from a significant portion of the global population. The MONARCH plus trial, primarily conducted in the Chinese population with HR + /HER2- advanced breast cancer, randomized patients to receive anastrozole/letrozole, fulvestrant plus abemaciclib, or a placebo. In cohort B of the MONARCH plus trial, 36 patients (34.6% of the experimental group, higher than in MONARCH-2) had primary resistance to ET. While OS data were not fully developed in the intention-to-treat (ITT) population, there were observable survival benefits in the primary endocrine-resistant group (HR = 0.348, 95% CI: 0.165–0.734) [34]. However, the clinical benefits of CDK4/6i plus ET therapy for endocrine-resistant population in other trials, MONALEESA-3 (ribociclib + fulvestrant) and PALOMA-3 (palbociclib + fulvestrant), are not observed [35–38]. Based on current clinical trial results, abemaciclib is the preferred option for those with primary endocrine resistance, whereas ribociclib or palbociclib does not provide advantages for individuals with primary endocrine resistance. Notably, Dalpiciclib has not been subject to clinical study focusing on endocrine-resistant population. Recently, lerociclib, a novel CDK4/6i, demonstrates superior efficacy in patients with endocrine resistance. The LEONARDA-1, a phase 3 trial, assessed lerociclib plus fulvestrant versus a placebo in patients who had experienced relapse or progression on prior ET. Among these patients, 25.5% exhibited primary endocrine resistance (24.8% in the lerociclib + fulvestrant group versus 26.1% in the placebo + fulvestrant group). The results demonstrated a significantly prolonged PFS in the lerociclib group compared to the placebo group (HR = 0.45, P < 0.001). Efficacy remained consistent across all subgroups, including those with primary endocrine resistance, showing a significantly reduced risk of disease progression or death with lerociclib (HR = 0.374, 95% CI: 0.182–0.769) [39].

Rechallenging treatment with an alternative CDK4/6i after disease progression on prior CDK4/6i therapy has been recommended by both domestic and international guidelines. A retrospective analysis of 87 patients with HR+ advanced breast cancer at 6 U.S. cancer centers revealed that using abemaciclib following palbociclib therapy resulted in a mPFS of 5.3 months and an OS of 17.2 months, suggesting potential benefits for heavily pretreated patients [40]. The MAINTAIN trial, a phase II study in advanced HR + /HER2- breast cancer, assessed fulvestrant or exemestane combined with ribociclib or placebo. Notably, 84% of patients had previously received palbociclib, allowing for potential rechallenge with ribociclib-based endocrine therapy. Results presented at the 2022 ASCO Annual Meeting indicated a mPFS of 5.29 months with ribociclib compared to 2.76 months with a placebo. This represents the first prospective randomized controlled study demonstrating the benefit of switching to another CDK4/6i in advanced HR + /HER2- breast cancer patients [41]. However, the approach may not be effective if patients exhibit Rb loss in their tumors, as suggested by the BioPER trial [42]. Currently, there is limited data available on cross-line therapy following CDK4/6i progression, emphasizing the need for large, randomized trials in the future.

Application in patients with bone metastases

Bone metastases are common in breast cancer, with nearly 70% of advanced breast cancer patients developing bone metastasis (BM) [43, 44]. These metastases often result in skeletal-related events (SREs), such as pain, pathological fractures, and spinal cord or spinal nerve compression, significantly impacting patients’ quality of life and OS [45, 46]. Clinical studies indicate that HR + /HER2- breast cancer has a higher propensity for BM [47]. Recent evidence suggests that CDK4/6i provide a PFS benefit, particularly in breast cancer patients with bone-only disease, leading to extended disease control and improved survival [48, 49].

The PALOMA-2, MONALEESA-2, and MONARCH-3 trials assessed the efficacy of combining ET with CDK4/6i (palbociclib, ribociclib, abemaciclib) as a first-line treatment for HR + /HER2- MBC, including subgroup analyses on patients with exclusive bone metastases [18, 19, 36, 50–52]. In the PALOMA-2 trial, the combination of palbociclib and AI significantly extended PFS to 27.6 months, reducing the risk of disease progression by 44% in the overall population. The most significant benefit was observed in patients with BM (mPFS: 36.2 months, reduction in the risk of disease progression: 59%) [53]. In the meanwhile, both the MONALEESA-2 and MONARCH-3 trials showed a relative PFS benefit in patients with exclusive bone involvement during exploratory subgroup analyses of the combination of abemaciclib and AI (MONALEESA-2: HR = 0.69, 95% CI: 0.38–1.25; MONARCH-3: HR = 0.58, 95% CI: 0.27–1.25). However, these findings did not achieve statistical significance due to the fact that mPFS was not reached in both groups [2, 54]. In a meta-analysis of seven Phase III randomized controlled trials (RCTs, including PALOMA-2, MONALEESA-2, MONALEESA-7, MONARCH-3, FALCON, SWOG, and FACT), the objective was to determine whether CDK4/6i should serve as the first-line treatment for all patients with HR + /HER2- MBC. The findings indicated a significant enhancement in both PFS and ORR when CDK4/6i were administered to patients with BM [55]. Furthermore, all three classic CDK4/6i exhibited comparable efficacy and had the potential to mitigate disease progression in breast cancer patients with BM [56–58].

The PALOMA-3, MONALEESA-3, and MONARCH-2 trials investigated the suitability of CDK4/6i as a treatment option for patients with endocrine-resistant breast cancer and BM. They showed that CDK4/6i plus fulvestrant significantly improved PFS in patients with bone-only metastases (PALOMA-3: HR = 0.43, 95% CI: 0.28–0.67; MONALEESA-3: HR = 0.379, 95% CI: 0.234–0.613; MONARCH-2: HR = 0.543, 95% CI: 0.355–0.833) [27, 58–60]. In conclusion, both endocrine-sensitive and endocrine-resistant HR + /HER2- breast cancer patients with BM can benefit from CDK4/6i treatment.

Application in patients with visceral metastases

Visceral metastasis (VM), occurring in over 50% of advanced HR + /HER2- breast cancer patients, is an independent poor prognosis risk factor [61–63]. Current clinical practice shows no significant improvement with endocrine monotherapy in VM patients [64–67]. A meta-analysis suggests that VM patients benefit from ET combined with CDK4/6i, while endocrine monotherapy offers limited advantages [68]. Various CDK4/6i combined with AI provide remarkable benefits in endocrine-sensitive patients. Trials like PALOMA-2 (palbociclib plus letrozole, 394 VM patients), MONARCH-3 (abemaciclib plus anastrozole/letrozole, 261 VM patients), MONALEESA-2 (ribociclib plus letrozole, 393 VM patients), and DAWNA-2 (dalpicilib plus letrozole/anastrozole, 277 VM patients) have shown that CDK4/6i combined with AI significantly extend PFS in VM subgroups (HR = 0.561–0.63, 95% CI: 0.408–0.90) [2, 18, 19, 24]. Furthermore, the combination of CDK4/6i and fulvestrant is effective in endocrine-resistant populations. Trials such as PALOMA-2 (311 VM patients), MONARCH-2 (373 VM patients), MONALEESA-3 (439 VM patients), and DAWNA-1 (217 VM patients) have included VM patients. The addition of palbociclib, abemaciclib, ribociclib, or dalpicilib to fulvestrant has significantly improved both PFS (HR = 0.47–0.675, 95% CI: 0.33–0.779) and OS (HR = 0.675, 95% CI: 0.511–0.891) [18, 24, 25, 27, 33, 58]. Thus, endocrine resistance is not a barrier for VM patients, and combining CDK4/6i with fulvestrant presents a promising strategy. Notably, the toxicity of CDK4/6i should be taken into consideration when administering them to patients with VM. Neutropenia, diarrhea, Corrected QT intervals (QTc) prolongation and hepatobiliary toxicity are the key adverse events. As for patients with liver metastasis, the AST/ALT examination is necessary to be performed before CDK4/6i administration.

Additionally, it’s crucial to assess the specific organ sites, organ function, and bone marrow status when considering CDK4/6i combination therapies for VM patients. While the FALCON study’s VM subgroup analysis didn’t show a significant advantage of fulvestrant over anastrozole [64], a retrospective study indicated that patients with non-liver visceral metastases had better therapeutic responses to fulvestrant compared to those with liver metastases across all treatment lines [69]. These findings emphasize the importance of considering specific metastatic sites as independent prognostic factors when making treatment decisions, including rare locations like the brain, meninges, bone marrow, and spinal cord. Such considerations can impact the choice of CDK4/6i. Moreover, it’s essential to avoid CDK4/6i that may exacerbate liver dysfunction in clinical practice to prevent drug-induced liver injury [70, 71]. Evaluating the patient’s baseline bone marrow function is necessary to determine whether they can tolerate the hematologic side effects of CDK4/6i in cases of bone marrow metastases [72, 73]. For patients with brain or meninges metastases, it’s advisable to consider the blood-brain barrier penetration effects of different CDK4/6i based on available exploratory data [74].

Breast cancer with visceral crisis (VC) refers to patients experiencing both VM and the associated symptoms and signs. The latest definition of VC, according to the ESO-ESMO 5th Advanced Breast Cancer (ABC5) guideline, characterizes it as “severe organ dysfunction assessed through signs, symptoms, laboratory tests, and rapid disease progression” [75]. Historically, chemotherapy (CT) was recommended for this urgent, life-threatening condition. However, some patients couldn’t endure the strong cytotoxic effects of CT due to poor liver function [76–78]. The introduction of CDK4/6i has overturned the notion of slow-acting ET drugs and has brought forth an optimal therapeutic strategy with good efficacy and fewer adverse events [79]. Recent findings indicate that CT does not offer superior outcomes compared to CDK4/6i when used in combination with ET for first/second-line treatment of HR + /HER2- MBC, especially concerning PFS [80]. Real-world data also supports the use of CDK4/6i in cases of VC, showing a significant 5-month improvement in OS compared to CT [81]. Moreover, a recent case report has questioned the traditional approach of using CT for all patients with VC, proposing the possibility of employing CDK4/6i in poor prognostic scenarios [82]. The RIGHT Choice, a randomized, phase II, open-label, multicenter clinical trial presented at the 2022 San Antonio Breast Cancer Symposium (SABCS), offered the first head-to-head comparison of CDK4/6i plus ET versus CT in advanced HR + /HER2- breast cancer with life-threatening VC. With a median follow-up of 24.1 months, ribociclib plus ET led to a significant improvement in mPFS, extending it from 12.3 months to 24.0 months compared to the CT group. This approach also notably reduced the risk of progression or death (HR = 0.54; 95% CI: 0.36–0.79; P = 0.0007). Comparable improvements were observed in ORR (65.2% vs. 60.0%), CBR (80.4% vs. 72.7%), and time to remission (TTR) (4.9 months vs. 3.2 months; HR = 0.78, 95% CI: 0.56–1.09) in the ribociclib group compared to CT. Hence, ribociclib combined with ET emerges as a preferred choice for patients with VC [83]. These findings collectively emphasize the potential of CDK4/6i in the management of advanced breast cancer, offering more tailored and effective treatment options for patients in VC.

CDK4/6i in combination with HER2-targeted therapy

Compared to HR + /HER2- breast cancer, HR + /HER2+ breast cancer exhibits a more aggressive nature and diminished sensitivity to ET and HER2-targeted therapy, resulting in a poorer prognosis. Recent studies have unveiled the underlying mechanisms. The HER2 pathway has been linked to heightened endoplasmic reticulum phosphorylation and has demonstrated endoplasmic reticulum’s role in fostering resistance to ET [84, 85]. Moreover, CDK4/6, positioned downstream of the HER2 signaling pathway, plays a pivotal role in conferring resistance to HER2-targeted therapy [86]. Hence, CDK4/6 emerges as an attractive target to enhance the survival prospects of HR + /HER2+ breast cancer patients. Research has shown that HER2 significantly boosts CDK4/6 activity through phosphorylated Rb (pRb) in HER2+ breast cancer, suggesting the potential responsiveness of HER2+ breast cancer to CDK4/6i [87]. The combination of palbociclib with either tamoxifen or trastuzumab has demonstrated inhibitory effects in both ER+ and HER2+ cell lines [88]. Preclinical data support the notion that CDK4/6i can overcome resistance to HER2-targeted therapies, thereby delaying recurrence in HER2+ breast cancer patients [89]. Moreover, several clinical trials have substantiated the antitumor efficacy of CDK4/6i in HR + /HER2+ breast cancer (Table 2). The monarcHER and PATRIICA trials have revealed a synergistic benefit in the co-inhibition of CDK4/6 and HER2 for the treatment of advanced HR + /HER2+ breast cancer [90, 91]. The DAP-Her-01 study was the first to assess the efficacy and safety of orally administered dalpiciclib and HER2 tyrosine kinase inhibitor (TKI) pyrotinib as a first-line treatment for HER2+ advanced breast cancer. After a median follow-up of 25.9 months, the ORR was 70% (95% CI: 53.5–83.4%), with a mPFS of 11.0 months (95% CI: 7.3–19.3 months), while OS data were still pending. Additionally, findings from the DAP-HER-01 study have indicated that the combination of dalpiciclib and pyrotinib holds promise as an optimal strategy for HER2+ breast cancer patients with brain metastases [92]. Notably, nearly half of patients with HER2 + MBC will eventually develop brain metastases [93]. Consequently, identifying novel systemic therapies capable of effectively penetrating the blood-brain barrier (BBB) and concurrently targeting extracranial disease is an appealing strategy. Previous studies have suggested that abemaciclib attains higher central nervous system concentrations at a potentially lower dose compared to palbociclib [94]. Currently, a trial (DAP-HER-02, NCT05328440) investigating first-line treatment for HER2+ advanced breast cancer with a combination of dalpiciclib and pyrotinib, along with fulvestrant or inetetamab, is currently underway.Table 2 Summary of clinical trials evaluating CDK4/6 inhibitors in combination with HER2-targeted therapy or immunotherapy.

Trial	Phase	N	Treatments	Primary endpoint Results	
monarcHER (NCT02675231)	II	325	Abemaciclib+Trastuzumab+Fulvestrant (A)

Abemaciclib+Trastuzumab(B)

Chemotherapy+Trastuzumab(C)

	PFS between A and C 8.3 vs 5.7 months

(HR = 0.673, 95% CI: 0.45-1.00)

	
PFS between B and C 5.7 vs 5.7 months

(HR = 0.94, 95% CI: 0.64-1.38)

	
PATRIICA (NCT02448420)	II	71	Palbociclib+Trastuzumab (ER-) / (ER + )

Palbociclib+Trastuzumab+letrozole(ER + )

	PFS6, n (%, 95% CI)

5 (33.3, 10.8–77.8) / 12 (42.9, 24.5–62.86)

13 (46.4, 27.5–66.1)

	
DAP-HER-01 (NCT04293276)	II	41	Dalpiciclib+Pyrotinib	mPFS in evaluable patients: 11.0 months (95% CI: 7.3-19.3)	
DAP-HER-02 (NCT05328440)	II		Dalpiciclib+Pyrotinib+Fulvestrant vs Inetetamab	Ongoing	
NCT02779751	Ib	54	Abemaciclib+Pembrolizumab+Anastrozole vs Abemaciclib+Pembrolizumab	Neutropenia (30.8/28.6%), AST increase (34.6/17.9%),

ALT increase (42.3/10.7%), and diarrhea (3.8/10.7%) were the most frequent grade ≥3 adverse events

	
CheckMate 7A8 (NCT04075604)	Ib/II	21	Palbociclib 125-mg/ 100-mg	DLTs 2 (22.2%)/ 0 patient	
Ib	6	Ribociclib 400 mg/ 600 mg + spartalizumab 400 mg	no DLTs were observed	
4	Ribociclib 600 mg+spartalizumab 400 mg	1/3 experienced a DLT of grade 3 atrial fibrillation and flutter	
NEWFLAME	II	17	Nivolumab+Abemaciclib+Fulvestrant vs Letrozole	ORR 54.5% (6/11) vs 40.0% (2/5)	
PFS progression-free survival, PFS6 progression-free survival rate at 6 months, mPFS median progression-free survival, DLTs dose-limiting toxicities, ORR objective response rate, HR hazard ratio, CI confidence interval.

CDK4/6i in combination with immunotherapy

CDK4/6i have demonstrated an enhancement of the antitumor immune response. Beyond their direct impact on tumor cells, they can influence immune cells within the tumor microenvironment. This influence plays a pivotal role in the proliferation and differentiation of T-cells, as well as in the chemokine-mediated recruitment of T-cells to mammary tumors. Preclinical studies have confirmed that CDK4/6i selectively inhibits regulatory T cells (Tregs) and dendritic cells (DC), which can induce immunological tolerance and suppress the immune response [95, 96]. These findings suggest that the use of CDK4/6i in treating tumors may render them more responsive to immunotherapy.

Currently, there are ongoing preclinical and clinical trials investigating the combination of CDK4/6i with immune checkpoint blockade (ICB) therapy for breast cancer. However, initial results indicate that adding ICB does not significantly enhance responses compared to CDK4/6i monotherapy (Table 2). For instance, the combination of abemaciclib with the anti-programmed death-1 (PD-1) antibody pembrolizumab, with or without ET, in patients with HR + /HER2- MBC who have not been previously exposed to CDK4/6i did not demonstrate a clear improvement when compared to abemaciclib monotherapy [97]. Similarly, combining palbociclib or ribociclib with the PD-1 inhibitor did not yield significant efficacy [98, 99]. Recently, the NEWFLAME trial, a phase II study, assessed the effectiveness of combining nivolumab, abemaciclib, and endocrine therapy (fulvestrant or letrozole) in patients with HR + /HER2- MBC. While the results indicated an antitumor response, they were accompanied by a high incidence of severe immune-related adverse events, which does not warrant further investigation [100].

Mechanism of action of CDK4/6 inhibitors

Mechanistically, ATP-competitive CDK4/6 dual inhibitors such as abemaciclib, palbociclib and ribociclib, block CDK4/6, stop the phosphorylation of Rb and arrest G1 cell cycle development of tumor cells. In terms of molecular structure, the substituents in hydrophobic post-pocket of abemaciclib (2 fluorine atoms) is smaller than that of palbociclib and ribociclib (dimethylatmide and acethal groups) [101]. This difference may result in lower kinase selectivity of abemaciclib compared to the other two CDK4/6i. It also leads to different adverse reactions of the three CDK4/6i. Abemaciclib stands out among CDK4/6 inhibitors with its higher CDK4/6 inhibitory constant (Ki) ATP ratio, emphasizing its stronger selectivity for CDK4 but lower selectivity for CDK6. This unique attribute not only enhances its effectiveness in inhibiting breast cancer cell proliferation but also reduces the risk of bone marrow toxicity. Interestingly, the most common adverse event in palbociclib and ribociclib is neutropenia [102]. Additionally, palbociclib and ribociclib can only inhibit CDK4 and CDK6, whereas abemaciclib also has an activity against CDK9, which may related to intestinal toxicity induced by abemaciclib specifically. Transaminase elevation and QT interval prolongation are also notable toxicities reported with ribociclib [103]. Due to extensive hepatic metabolism through the CYP3A4A pathway, CDK4/6i have been shown to have a serious effect on liver enzymes. Ribociclib is notorious for causing elevated transaminases with grade 3-4 toxicity occurred 7%-10% of the time [104]. Furthermore, the mechanism of QT prolongation is reported that ribociclib inhibits one or more kinases, which may modify ion channel protein function and potassium [105]. Overall, research on CDK4/6i toxicity is essential to strike a balance between the benefits of treatment and the potential risks to a patient’s health.

Summary

The introduction of CDK4/6i has significantly advanced the therapeutic landscape for HR+ breast cancer (Fig. 1). Currently, CDK4/6i combined with ET represent the standard first-line treatment for both premenopausal and postmenopausal women. In the endocrine-sensitive population, combining CDK4/6i with AI or fulvestrant has demonstrated comparable enhancements in PFS and OS. However, in the endocrine-resistant population, the combination of fulvestrant and CDK4/6i has yielded superior clinical benefits.Fig. 1 Regulation of cell cycle in breast cancer in CDK4/6 inhibitors.

AI, aromatase inhibitor (anastrozole, letrozole, exemestane); SERM, selective estrogen receptor modulator (Tamoxifen (TAM)); SERD, selective estrogen receptor down-regulator (fulvestrant); ER, estrogen receptor; E, estradiol; T testosterone; TKIs, tyrosine kinase inhibitors (pyrotinib, lapatinib); mAbs, (trastuzumab, pertuzumab); PI3Ki, Phosphoinositide 3-kinases inhibitor (alpelisib); AKTi, protein-kinase B inhibitor (capivasertib); mTORi, mammalian target of rapamycin inhibitor (everolimus); E2F, a transcription factor; Rb, retinoblastoma protein; HER2, human epidermal growth-factor receptor 2; HDACi, HDAC inhibitor (tucidinostat); PARPi, PARP inhibitor (olaparib, talazoparib); HRD, homologous recombination deficiency; CDK4/6 inhibitors, cyclin-dependent kinase 4/6 (Palbociclib, Ribociclib, Abemaciclib, Dalpiciclib).

BM are common in breast cancer, and CDK4/6i show promise in patients with bone-only metastases. However, in cases of VC, which are associated with a less favorable prognosis, endocrine monotherapy offers limited advantages. The decision to use CDK4/6i should be guided by the specific metastatic sites and organ functionality.

Furthermore, preclinical and clinical investigations have indicated that CDK4/6i can augment the response to HER2-targeted therapy. Additionally, CDK4/6i have shown the ability to enhance anti-tumor immune responses. However, ongoing research is evaluating the combination of CDK4/6i with ICB, with initial findings not demonstrating significant benefits. CDK4/6i and ICB monotherapy are shown to have overlapping toxicities, particularly hepatic events and interstitial lung disease/pneumonitis, and adverse events were found to be a leading cause of treatment discontinuation. Recent applications of CDK4/6i in neoadjuvant therapy for breast cancer are the subject of ongoing clinical trials. To summarize, CDK4/6i have revolutionized the management of HR+ breast cancer. These findings emphasize the significance of personalized treatment strategies for breast cancer patients.

Acknowledgements

This study was supported by Dalian Medical University Interdisciplinary Research Cooperation Project Team Funding (JCHZ2023009) of Man Li and Liaoning Province Science and Technology Plan Joint Fund Project - Doctoral Startup Fund of Kainan Wang.

Author contributions

XW, YZ, and QX conducted a systematic literature search. XW, SZ, and KW summarized and wrote the manuscript. KW and ML revised the manuscript. XW, SZ, YZ, and QX contributed equally to this paper.

Data availability

All data generated or analyzed during this study are included in this published article and referenced articles are listed in the References section.

Competing interests

The authors declare that they have no competing interests.

Ethical approval

This study involved a review; thus, no ethical approval or informed consent was required.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

These authors contributed equally: Xueqing Wang, Shanshan Zhao, Qinghan Xin, Yunkun Zhang.
==== Refs
References

1. Siegel RL Miller KD Wagle NS Jemal A Cancer statistics, 2023 CA Cancer J Clin 2023 73 17 48 10.3322/caac.21763 36633525
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17–48.36633525 10.3322/caac.21763
2. Goetz MP Toi M Campone M Sohn J Paluch-Shimon S Huober J MONARCH 3: abemaciclib as initial therapy for advanced breast cancer J Clin Oncol 2017 35 3638 46 10.1200/JCO.2017.75.6155 28968163
Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35:3638–46.28968163 10.1200/JCO.2017.75.6155
3. Sherr CJ Roberts JM CDK inhibitors: positive and negative regulators of G1-phase progression Genes Dev 1999 13 1501 12 10.1101/gad.13.12.1501 10385618
Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12.10385618 10.1101/gad.13.12.1501
4. Bertoli C Skotheim JM de Bruin RA Control of cell cycle transcription during G1 and S phases Nat Rev Mol Cell Biol 2013 14 518 28 10.1038/nrm3629 23877564
Bertoli C, Skotheim JM, de Bruin RA. Control of cell cycle transcription during G1 and S phases. Nat Rev Mol Cell Biol. 2013;14:518–28.23877564 10.1038/nrm3629
5. Spring LM Wander SA Andre F Moy B Turner NC Bardia A Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future Lancet 2020 395 817 27 10.1016/S0140-6736(20)30165-3 32145796
Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet. 2020;395:817–27.32145796 10.1016/S0140-6736(20)30165-3
6. Ding L Cao J Lin W Chen H Xiong X Ao H The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer Int J Mol Sci 2020 21 1960 10.3390/ijms21061960 32183020
Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, et al. The roles of cyclin-dependent kinases in cell-cycle progression and therapeutic strategies in human breast cancer. Int J Mol Sci. 2020;21:1960.32183020 10.3390/ijms21061960
7. Roskoski R Jr Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs Pharm Res 2019 139 471 88 10.1016/j.phrs.2018.11.035
Roskoski R Jr. Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs. Pharm Res. 2019;139:471–88.10.1016/j.phrs.2018.11.035
8. Pernas S Tolaney SM Winer EP Goel S CDK4/6 inhibition in breast cancer: current practice and future directions Ther Adv Med Oncol 2018 10 1758835918786451 10.1177/1758835918786451 30038670
Pernas S, Tolaney SM, Winer EP, Goel S. CDK4/6 inhibition in breast cancer: current practice and future directions. Ther Adv Med Oncol. 2018;10:1758835918786451.30038670 10.1177/1758835918786451
9. Alves CL Ehmsen S Terp MG Portman N Tuttolomondo M Gammelgaard OL Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer Nat Commun 2021 12 5112 10.1038/s41467-021-25422-9 34433817
Alves CL, Ehmsen S, Terp MG, Portman N, Tuttolomondo M, Gammelgaard OL, et al. Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer. Nat Commun. 2021;12:5112.34433817 10.1038/s41467-021-25422-9
10. Xu B Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author’s reply Lancet Oncol 2023 24 e357 10.1016/S1470-2045(23)00361-3 37657472
Xu B. Dalpiciclib in advanced breast cancer: introducing CDK4/6 inhibitors as a first-line treatment might not be the best strategy - Author’s reply. Lancet Oncol. 2023;24:e357.37657472 10.1016/S1470-2045(23)00361-3
11. Lelliott EJ Kong IY Zethoven M Ramsbottom KM Martelotto LG Meyran D CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memory Cancer Discov 2021 11 2582 601 10.1158/2159-8290.CD-20-1554 33990344
Lelliott EJ, Kong IY, Zethoven M, Ramsbottom KM, Martelotto LG, Meyran D, et al. CDK4/6 inhibition promotes antitumor immunity through the induction of T-cell memory. Cancer Discov. 2021;11:2582–601.33990344 10.1158/2159-8290.CD-20-1554
12. Goel S DeCristo MJ Watt AC BrinJones H Sceneay J Li BB CDK4/6 inhibition triggers anti-tumour immunity Nature 2017 548 471 5 10.1038/nature23465 28813415
Goel S, DeCristo MJ, Watt AC, BrinJones H, Sceneay J, Li BB, et al. CDK4/6 inhibition triggers anti-tumour immunity. Nature. 2017;548:471–5.28813415 10.1038/nature23465
13. Schettini F Giuliano M Giudici F Conte B De Placido P Venturini S Endocrine-based treatments in clinically-relevant subgroups of hormone receptor-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis Cancers (Basel) 2021 13 1458 10.3390/cancers13061458 33810205
Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, et al. Endocrine-based treatments in clinically-relevant subgroups of hormone receptor-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis. Cancers (Basel). 2021;13:1458.33810205 10.3390/cancers13061458
14. Wang J Han Y Wang J Li Q Xu B Endocrine therapy-based strategies for metastatic breast cancer with different endocrine sensitivity statuses: a systematic review and network meta-analysis Cancers (Basel) 2022 14 6100 10.3390/cancers14246100 36551586
Wang J, Han Y, Wang J, Li Q, Xu B. Endocrine therapy-based strategies for metastatic breast cancer with different endocrine sensitivity statuses: a systematic review and network meta-analysis. Cancers (Basel). 2022;14:6100.36551586 10.3390/cancers14246100
15. Lukas J Bartkova J Bartek J Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint Mol Cell Biol 1996 16 6917 25 10.1128/MCB.16.12.6917 8943347
Lukas J, Bartkova J, Bartek J. Convergence of mitogenic signalling cascades from diverse classes of receptors at the cyclin D-cyclin-dependent kinase-pRb-controlled G1 checkpoint. Mol Cell Biol. 1996;16:6917–25.8943347 10.1128/MCB.16.12.6917
16. De Marchi T Foekens JA Umar A Martens JW Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer Drug Discov Today 2016 21 1181 8 10.1016/j.drudis.2016.05.012 27233379
De Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016;21:1181–8.27233379 10.1016/j.drudis.2016.05.012
17. Rugo HS Rumble RB Macrae E Barton DL Connolly HK Dickler MN Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline J Clin Oncol 2016 34 3069 103 10.1200/JCO.2016.67.1487 27217461
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016;34:3069–103.27217461 10.1200/JCO.2016.67.1487
18. Finn RS Martin M Rugo HS Jones S Im SA Gelmon K Palbociclib and letrozole in advanced breast cancer N Engl J Med 2016 375 1925 36 10.1056/NEJMoa1607303 27959613
Finn RS, Martin M, Rugo HS, Jones S, Im SA, Gelmon K, et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375:1925–36.27959613 10.1056/NEJMoa1607303
19. Hortobagyi GN Stemmer SM Burris HA Yap YS Sonke GS Paluch-Shimon S Ribociclib as first-line therapy for HR-positive, advanced breast cancer N. Engl J Med 2016 375 1738 48 10.1056/NEJMoa1609709 27717303
Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, et al. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N. Engl J Med. 2016;375:1738–48.27717303 10.1056/NEJMoa1609709
20. Brett JO Spring LM Bardia A Wander SA ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer Breast Cancer Res 2021 23 85 10.1186/s13058-021-01462-3 34392831
Brett JO, Spring LM, Bardia A, Wander SA. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer. Breast Cancer Res. 2021;23:85.34392831 10.1186/s13058-021-01462-3
21. Bardia A Hurvitz S Targeted therapy for premenopausal women with HR(+), HER2(-) advanced breast cancer: focus on special considerations and latest advances Clin Cancer Res 2018 24 5206 18 10.1158/1078-0432.CCR-18-0162 29884743
Bardia A, Hurvitz S. Targeted therapy for premenopausal women with HR(+), HER2(-) advanced breast cancer: focus on special considerations and latest advances. Clin Cancer Res. 2018;24:5206–18.29884743 10.1158/1078-0432.CCR-18-0162
22. Tripathy D Im SA Colleoni M Franke F Bardia A Harbeck N Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial Lancet Oncol 2018 19 904 15 10.1016/S1470-2045(18)30292-4 29804902
Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, et al. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018;19:904–15.29804902 10.1016/S1470-2045(18)30292-4
23. Im SA Lu YS Bardia A Harbeck N Colleoni M Franke F Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer N. Engl J Med 2019 381 307 16 10.1056/NEJMoa1903765 31166679
Im SA, Lu YS, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. N. Engl J Med. 2019;381:307–16.31166679 10.1056/NEJMoa1903765
24. Zhang P Zhang Q Tong Z Sun T Li W Ouyang Q Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Lancet Oncol 2023 24 646 57 10.1016/S1470-2045(23)00172-9 37182538
Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646–57.37182538 10.1016/S1470-2045(23)00172-9
25. Slamon DJ Neven P Chia S Fasching PA De Laurentiis M Im SA Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3 J Clin Oncol 2018 36 2465 72 10.1200/JCO.2018.78.9909 29860922
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36:2465–72.29860922 10.1200/JCO.2018.78.9909
26. Slamon DJ Neven P Chia S Jerusalem G De Laurentiis M Im S Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival Ann Oncol 2021 32 1015 24 10.1016/j.annonc.2021.05.353 34102253
Slamon DJ, Neven P, Chia S, Jerusalem G, De Laurentiis M, Im S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021;32:1015–24.34102253 10.1016/j.annonc.2021.05.353
27. Slamon DJ Neven P Chia S Fasching PA De Laurentiis M Im SA Overall survival with ribociclib plus fulvestrant in advanced breast cancer N. Engl J Med 2020 382 514 24 10.1056/NEJMoa1911149 31826360
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N. Engl J Med. 2020;382:514–24.31826360 10.1056/NEJMoa1911149
28. Slamon DJ Neven P Chia S Fasching PA De Laurentiis M Im SA Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB) Ann Oncol 2019 30 v856 v7 10.1093/annonc/mdz394.007
Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Ann Oncol. 2019;30:v856–v7.10.1093/annonc/mdz394.007
29. Albanell J Martínez MT Ramos M O’Connor M de la Cruz-Merino L Santaballa A Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER) Eur J Cancer 2022 161 26 37 10.1016/j.ejca.2021.11.010 34902765
Albanell J, Martínez MT, Ramos M, O’Connor M, de la Cruz-Merino L, Santaballa A, et al. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). Eur J Cancer. 2022;161:26–37.34902765 10.1016/j.ejca.2021.11.010
30. Tibau A Martínez MT Ramos M De La Cruz-Merino L Santaballa A O’Connor M Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial Ther Adv Med Oncol 2023 15 17588359221148921 10.1177/17588359221148921 36743520
Tibau A, Martínez MT, Ramos M, De La Cruz-Merino L, Santaballa A, O’Connor M, et al. Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial. Ther Adv Med Oncol. 2023;15:17588359221148921.36743520 10.1177/17588359221148921
31. Llombart-Cussac A Pérez-García JM Bellet M Dalenc F Gil-Gil M Ruíz-Borrego M Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial JAMA Oncol 2021 7 1791 9 10.1001/jamaoncol.2021.4301 34617955
Llombart-Cussac A, Pérez-García JM, Bellet M, Dalenc F, Gil-Gil M, Ruíz-Borrego M, et al. Fulvestrant-palbociclib vs letrozole-palbociclib as initial therapy for endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer: a randomized clinical trial. JAMA Oncol. 2021;7:1791–9.34617955 10.1001/jamaoncol.2021.4301
32. Di Cosimo S Pérez-García JM Bellet M Dalenc F Gil Gil MJ Ruiz Borrego M Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-positive/HER2-negative advanced breast cancer: a detailed safety analysis of the randomized PARSIFAL Trial Oncologist 2023 28 23 32 10.1093/oncolo/oyac205 36239405
Di Cosimo S, Pérez-García JM, Bellet M, Dalenc F, Gil Gil MJ, Ruiz Borrego M, et al. Palbociclib with fulvestrant or letrozole in endocrine-sensitive patients with HR-positive/HER2-negative advanced breast cancer: a detailed safety analysis of the randomized PARSIFAL Trial. Oncologist. 2023;28:23–32.36239405 10.1093/oncolo/oyac205
33. Sledge GW Jr Toi M Neven P Sohn J Inoue K Pivot X The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial JAMA Oncol 2020 6 116 24 10.1001/jamaoncol.2019.4782 31563959
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol. 2020;6:116–24.31563959 10.1001/jamaoncol.2019.4782
34. Zhang QY Sun T Yin YM Li HP Yan M Tong ZS MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study Ther Adv Med Oncol 2020 12 1758835920963925 10.1177/1758835920963925 33149768
Zhang QY, Sun T, Yin YM, Li HP, Yan M, Tong ZS, et al. MONARCH plus: abemaciclib plus endocrine therapy in women with HR+/HER2- advanced breast cancer: the multinational randomized phase III study. Ther Adv Med Oncol. 2020;12:1758835920963925.33149768 10.1177/1758835920963925
35. Slamon DJ, Neven P, Chia SKL, Jerusalem GHM, Laurentiis MD, Im S-A, et al. Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). 39:1001 (2021).
36. Turner NC Slamon DJ Ro J Bondarenko I Im SA Masuda N Overall survival with palbociclib and fulvestrant in advanced breast cancer N. Engl J Med 2018 379 1926 36 10.1056/NEJMoa1810527 30345905
Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl J Med. 2018;379:1926–36.30345905 10.1056/NEJMoa1810527
37. Cristofanilli M Turner NC Bondarenko I Ro J Im SA Masuda N Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 2016 17 425 39 10.1016/S1470-2045(15)00613-0 26947331
Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17:425–39.26947331 10.1016/S1470-2045(15)00613-0
38. Xu B Zhang Q Zhang P Hu X Li W Tong Z Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial Nat Med 2021 27 1904 9 10.1038/s41591-021-01562-9 34737452
Xu B, Zhang Q, Zhang P, Hu X, Li W, Tong Z, et al. Dalpiciclib or placebo plus fulvestrant in hormone receptor-positive and HER2-negative advanced breast cancer: a randomized, phase 3 trial. Nat Med. 2021;27:1904–9.34737452 10.1038/s41591-021-01562-9
39. Xu B, Zhang Q, Luo Y, Tong Z, Sun T, Shan C, et al. LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy. 41:1017 (2023).
40. Wander SA, Han HS, Zangardi ML, Niemierko A, Mariotti V, Kim LSL, et al. Clinical outcomes with abemaciclib after prior CDK4/6 inhibitor progression in breast cancer: a multicenter experience. J Natl Compr Canc Netw. 1–8 (2021).
41. Kalinsky K Accordino MK Chiuzan C Mundi PS Sakach E Sathe C Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial J Clin Oncol 2023 41 4004 13 10.1200/JCO.22.02392 37207300
Kalinsky K, Accordino MK, Chiuzan C, Mundi PS, Sakach E, Sathe C, et al. Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol. 2023;41:4004–13.37207300 10.1200/JCO.22.02392
42. Albanell J Pérez-García JM Gil-Gil M Curigliano G Ruíz-Borrego M Comerma L Palbociclib rechallenge for hormone receptor-positive/HER-negative advanced breast cancer: findings from the phase II BioPER trial Clin Cancer Res 2023 29 67 80 10.1158/1078-0432.CCR-22-1281 36165912
Albanell J, Pérez-García JM, Gil-Gil M, Curigliano G, Ruíz-Borrego M, Comerma L, et al. Palbociclib rechallenge for hormone receptor-positive/HER-negative advanced breast cancer: findings from the phase II BioPER trial. Clin Cancer Res. 2023;29:67–80.36165912 10.1158/1078-0432.CCR-22-1281
43. Kennecke H Yerushalmi R Woods R Cheang MC Voduc D Speers CH Metastatic behavior of breast cancer subtypes J Clin Oncol 2010 28 3271 7 10.1200/JCO.2009.25.9820 20498394
Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28:3271–7.20498394 10.1200/JCO.2009.25.9820
44. Weigelt B Peterse JL van ‘t Veer LJ Breast cancer metastasis: markers and models Nat Rev Cancer 2005 5 591 602 10.1038/nrc1670 16056258
Weigelt B, Peterse JL, van ‘t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5:591–602.16056258 10.1038/nrc1670
45. Coleman RE Clinical features of metastatic bone disease and risk of skeletal morbidity Clin Cancer Res 2006 12 6243s 9s 10.1158/1078-0432.CCR-06-0931 17062708
Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12:6243s–9s.17062708 10.1158/1078-0432.CCR-06-0931
46. Ban J Fock V Aryee DNT Kovar H Mechanisms, diagnosis and treatment of bone metastases Cells 2021 10 2944 10.3390/cells10112944 34831167
Ban J, Fock V, Aryee DNT, Kovar H. Mechanisms, diagnosis and treatment of bone metastases. Cells. 2021;10:2944.34831167 10.3390/cells10112944
47. Parkes A Clifton K Al-Awadhi A Oke O Warneke CL Litton JK Characterization of bone only metastasis patients with respect to tumor subtypes NPJ Breast Cancer 2018 4 2 10.1038/s41523-018-0054-x 29387785
Parkes A, Clifton K, Al-Awadhi A, Oke O, Warneke CL, Litton JK, et al. Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer. 2018;4:2.29387785 10.1038/s41523-018-0054-x
48. Elfgen C Bjelic-Radisic V Targeted therapy in HR+ HER2- metastatic breast cancer: current clinical trials and their implications for CDK4/6 inhibitor therapy and beyond treatment options Cancers (Basel) 2021 13 5994 10.3390/cancers13235994 34885105
Elfgen C, Bjelic-Radisic V. Targeted therapy in HR+ HER2- metastatic breast cancer: current clinical trials and their implications for CDK4/6 inhibitor therapy and beyond treatment options. Cancers (Basel). 2021;13:5994.34885105 10.3390/cancers13235994
49. Mahtani RL Vogel CL Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer Cancer Manag Res 2019 11 513 24 10.2147/CMAR.S186658 30655702
Mahtani RL, Vogel CL. Addressing physician barriers to administering cyclin-dependent kinases 4 and 6 inhibitors in first-line treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Cancer Manag Res. 2019;11:513–24.30655702 10.2147/CMAR.S186658
50. Turner NC Ro J André F Loi S Verma S Iwata H Palbociclib in hormone-receptor-positive advanced breast cancer N. Engl J Med 2015 373 209 19 10.1056/NEJMoa1505270 26030518
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N. Engl J Med. 2015;373:209–19.26030518 10.1056/NEJMoa1505270
51. Hortobagyi GN Stemmer SM Burris HA III Yap YS Sonke GS Hart L LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB) Ann Oncol 2021 32 S1290 S1 10.1016/j.annonc.2021.08.2090
Hortobagyi GN, Stemmer SM, Burris HA III, Yap YS, Sonke GS, Hart L, et al. LBA17 Overall survival (OS) results from the phase III MONALEESA-2 (ML-2) trial of postmenopausal patients (pts) with hormone receptor positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) advanced breast cancer (ABC) treated with endocrine therapy (ET) ± ribociclib (RIB). Ann Oncol. 2021;32:S1290–S1.10.1016/j.annonc.2021.08.2090
52. Johnston S Martin M Di Leo A Im SA Awada A Forrester T MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer NPJ Breast Cancer 2019 5 5 10.1038/s41523-018-0097-z 30675515
Johnston S, Martin M, Di Leo A, Im SA, Awada A, Forrester T, et al. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.30675515 10.1038/s41523-018-0097-z
53. Rugo HS Finn RS Diéras V Ettl J Lipatov O Joy AA Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up Breast Cancer Res Treat 2019 174 719 29 10.1007/s10549-018-05125-4 30632023
Rugo HS, Finn RS, Diéras V, Ettl J, Lipatov O, Joy AA, et al. Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up. Breast Cancer Res Treat. 2019;174:719–29.30632023 10.1007/s10549-018-05125-4
54. Burris H Chan A Campone M Blackwell K Winer E Janni W Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trial Cancer Res 2017 77 P4-22-16 P4-22-16 10.1158/1538-7445.SABCS16-P4-22-16
Burris H, Chan A, Campone M, Blackwell K, Winer E, Janni W, et al. Abstract P4-22-16: First-line ribociclib + letrozole in patients with HR+, HER2– advanced breast cancer (ABC) presenting with visceral metastases or bone-only disease: a subgroup analysis of the MONALEESA-2 trial. Cancer Res. 2017;77:P4-22-16–P4-22-16.10.1158/1538-7445.SABCS16-P4-22-16
55. Rossi V Berchialla P Giannarelli D Nisticò C Ferretti G Gasparro S Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials Cancers (Basel) 2019 11 1661 10.3390/cancers11111661 31717791
Rossi V, Berchialla P, Giannarelli D, Nisticò C, Ferretti G, Gasparro S, et al. Should All Patients With HR-Positive HER2-Negative Metastatic Breast Cancer Receive CDK 4/6 Inhibitor As First-Line Based Therapy? A Network Meta-Analysis of Data from the PALOMA 2, MONALEESA 2, MONALEESA 7, MONARCH 3, FALCON, SWOG and FACT Trials. Cancers (Basel). 2019;11:1661.31717791 10.3390/cancers11111661
56. Hortobagyi GN Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial Breast Cancer Res 2018 20 123 10.1186/s13058-018-1050-7 30340505
Hortobagyi GN. Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. Breast Cancer Res. 2018;20:123.30340505 10.1186/s13058-018-1050-7
57. Serra F Lapidari P Quaquarini E Tagliaferri B Sottotetti F Palumbo R Palbociclib in metastatic breast cancer: current evidence and real-life data Drugs Context 2019 8 212579 10.7573/dic.212579 31391852
Serra F, Lapidari P, Quaquarini E, Tagliaferri B, Sottotetti F, Palumbo R. Palbociclib in metastatic breast cancer: current evidence and real-life data. Drugs Context. 2019;8:212579.31391852 10.7573/dic.212579
58. Sledge GW Jr Toi M Neven P Sohn J Inoue K Pivot X MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy J Clin Oncol 2017 35 2875 84 10.1200/JCO.2017.73.7585 28580882
Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35:2875–84.28580882 10.1200/JCO.2017.73.7585
59. Turner NC Finn RS Martin M Im SA DeMichele A Ettl J Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases Ann Oncol 2018 29 669 80 10.1093/annonc/mdx797 29342248
Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018;29:669–80.29342248 10.1093/annonc/mdx797
60. Goetz M O’Shaughnessy J Sledge G Jr Martin M Lin Y Forrester T Abstract GS6-02: the benefit of abemaciclib in prognostic subgroups: an exploratory analysis of combined data from the MONARCH 2 and 3 studies Cancer Res 2018 78 GS6-02-GS6 10.1158/1538-7445.SABCS17-GS6-02
Goetz M, O’Shaughnessy J, Sledge G Jr, Martin M, Lin Y, Forrester T, et al. Abstract GS6-02: the benefit of abemaciclib in prognostic subgroups: an exploratory analysis of combined data from the MONARCH 2 and 3 studies. Cancer Res. 2018;78:GS6-02-GS6.10.1158/1538-7445.SABCS17-GS6-02
61. Solomayer EF Diel IJ Meyberg GC Gollan C Bastert G Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis Breast Cancer Res Treat 2000 59 271 8 10.1023/A:1006308619659 10832597
Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G. Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat. 2000;59:271–8.10832597 10.1023/A:1006308619659
62. Harb WA Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options Cancer Manag Res 2015 7 37 46 10.2147/CMAR.S72592 25653556
Harb WA. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res. 2015;7:37–46.25653556 10.2147/CMAR.S72592
63. Rosa Mendoza ES Moreno E Caguioa PB Predictors of early distant metastasis in women with breast cancer J Cancer Res Clin Oncol 2013 139 645 52 10.1007/s00432-012-1367-z 23283528
Rosa Mendoza ES, Moreno E, Caguioa PB. Predictors of early distant metastasis in women with breast cancer. J Cancer Res Clin Oncol. 2013;139:645–52.23283528 10.1007/s00432-012-1367-z
64. Robertson JFR Bondarenko IM Trishkina E Dvorkin M Panasci L Manikhas A Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial Lancet 2016 388 2997 3005 10.1016/S0140-6736(16)32389-3 27908454
Robertson JFR, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388:2997–3005.27908454 10.1016/S0140-6736(16)32389-3
65. Robertson JF Llombart-Cussac A Rolski J Feltl D Dewar J Macpherson E Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study J Clin Oncol 2009 27 4530 5 10.1200/JCO.2008.21.1136 19704066
Robertson JF, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, Macpherson E, et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27:4530–5.19704066 10.1200/JCO.2008.21.1136
66. Robertson JF Lindemann JP Llombart-Cussac A Rolski J Feltl D Dewar J Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study Breast Cancer Res Treat 2012 136 503 11 10.1007/s10549-012-2192-4 23065000
Robertson JF, Lindemann JP, Llombart-Cussac A, Rolski J, Feltl D, Dewar J, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized ‘FIRST’ study. Breast Cancer Res Treat. 2012;136:503–11.23065000 10.1007/s10549-012-2192-4
67. Ellis MJ Llombart-Cussac A Feltl D Dewar JA Jasiówka M Hewson N Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study J Clin Oncol 2015 33 3781 7 10.1200/JCO.2015.61.5831 26371134
Ellis MJ, Llombart-Cussac A, Feltl D, Dewar JA, Jasiówka M, Hewson N, et al. Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol. 2015;33:3781–7.26371134 10.1200/JCO.2015.61.5831
68. Robertson JFR Di Leo A Johnston S Chia S Bliss JM Paridaens RJ Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies NPJ Breast Cancer 2021 7 11 10.1038/s41523-021-00222-y 33579962
Robertson JFR, Di Leo A, Johnston S, Chia S, Bliss JM, Paridaens RJ, et al. Meta-analyses of visceral versus non-visceral metastatic hormone receptor-positive breast cancer treated by endocrine monotherapies. NPJ Breast Cancer. 2021;7:11.33579962 10.1038/s41523-021-00222-y
69. He M Li JJ Zuo WJ Ji L Jiang YZ Hu XC Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant Cancer Med 2019 8 6212 20 10.1002/cam4.2453 31373147
He M, Li JJ, Zuo WJ, Ji L, Jiang YZ, Hu XC, et al. Metastatic breast cancer patients with lung or liver metastases should be distinguished before being treated with fulvestrant. Cancer Med. 2019;8:6212–20.31373147 10.1002/cam4.2453
70. Ettl J Management of adverse events due to cyclin-dependent kinase 4/6 inhibitors Breast Care (Basel) 2019 14 86 92 10.1159/000499534 31798379
Ettl J. Management of adverse events due to cyclin-dependent kinase 4/6 inhibitors. Breast Care (Basel). 2019;14:86–92.31798379 10.1159/000499534
71. Jahan N, Wongsaengsak S, Rehman S, Adhikari N, Tijani LA, Raghunath A. Relative risk of hepatotoxicity associated with cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials. 39:e13037-e (2021).
72. Kassem L Shohdy KS Lasheen S Abdel-Rahman O Bachelot T Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis Breast Cancer 2018 25 17 27 10.1007/s12282-017-0818-4 29147869
Kassem L, Shohdy KS, Lasheen S, Abdel-Rahman O, Bachelot T. Hematological adverse effects in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors: a systematic review and meta-analysis. Breast Cancer. 2018;25:17–27.29147869 10.1007/s12282-017-0818-4
73. Onesti CE Jerusalem G CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis Expert Rev Anticancer Ther 2021 21 283 98 10.1080/14737140.2021.1852934 33233970
Onesti CE, Jerusalem G. CDK4/6 inhibitors in breast cancer: differences in toxicity profiles and impact on agent choice. A systematic review and meta-analysis. Expert Rev Anticancer Ther. 2021;21:283–98.33233970 10.1080/14737140.2021.1852934
74. Schlam I Tolaney SM Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases? Oncotarget 2021 12 873 5 10.18632/oncotarget.27904 33953840
Schlam I, Tolaney SM. Is there a role for CDK 4/6 inhibitors in breast cancer brain metastases? Oncotarget. 2021;12:873–5.33953840 10.18632/oncotarget.27904
75. Cardoso F Paluch-Shimon S Senkus E Curigliano G Aapro MS André F 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) Ann Oncol 2020 31 1623 49 10.1016/j.annonc.2020.09.010 32979513
Cardoso F, Paluch-Shimon S, Senkus E, Curigliano G, Aapro MS, André F, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol. 2020;31:1623–49.32979513 10.1016/j.annonc.2020.09.010
76. Gennari A André F Barrios CH Cortés J de Azambuja E DeMichele A ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Ann Oncol 2021 32 1475 95 10.1016/j.annonc.2021.09.019 34678411
Gennari A, André F, Barrios CH, Cortés J, de Azambuja E, DeMichele A, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32:1475–95.34678411 10.1016/j.annonc.2021.09.019
77. Gradishar WJ Moran MS Abraham J Abramson V Aft R Agnese D NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 J Natl Compr Canc Netw 2023 21 594 608 10.6004/jnccn.2023.0031 37308117
Gradishar WJ, Moran MS, Abraham J, Abramson V, Aft R, Agnese D, et al. NCCN Guidelines® Insights: Breast Cancer, Version 4.2023. J Natl Compr Canc Netw. 2023;21:594–608.37308117 10.6004/jnccn.2023.0031
78. Burstein HJ Somerfield MR Barton DL Dorris A Fallowfield LJ Jain D Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline Update J Clin Oncol 2021 39 3959 77 10.1200/JCO.21.01392 34324367
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, et al. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO Guideline Update. J Clin Oncol. 2021;39:3959–77.34324367 10.1200/JCO.21.01392
79. Jiang Z Song E Geng C Pan Y Wang X Wang H Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022 Transl Breast Cancer Res 2022 3 13 10.21037/tbcr-22-21 38751537
Jiang Z, Song E, Geng C, Pan Y, Wang X, Wang H, et al. Chinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022. Transl Breast Cancer Res. 2022;3:13.38751537 10.21037/tbcr-22-21
80. Giuliano M Schettini F Rognoni C Milani M Jerusalem G Bachelot T Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis Lancet Oncol 2019 20 1360 9 10.1016/S1470-2045(19)30420-6 31494037
Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachelot T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20:1360–9.31494037 10.1016/S1470-2045(19)30420-6
81. Dawood SS, Brzozowski K Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database. 39:1047 (2021).
82. Schettini F Seguí E Conte B Sanfeliu E Gonzalez-Farre B Jares P Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report Front Oncol 2022 12 1009352 10.3389/fonc.2022.1009352 36425558
Schettini F, Seguí E, Conte B, Sanfeliu E, Gonzalez-Farre B, Jares P, et al. Intrinsic subtypes and therapeutic decision-making in hormone receptor-positive/HER2-negative metastatic breast cancer with visceral crisis: A case report. Front Oncol. 2022;12:1009352.36425558 10.3389/fonc.2022.1009352
83. Lu Y-S Mahidin EIBM Azim H ERALP Y Yap Y-S Im S-A Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy Cancer Res 2023 83 GS1–10 10.1158/1538-7445.SABCS22-GS1-10
Lu Y-S, Mahidin EIBM, Azim H, ERALP Y, Yap Y-S, Im S-A, et al. Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy. Cancer Res. 2023;83:GS1–10.10.1158/1538-7445.SABCS22-GS1-10
84. Wang YC Morrison G Gillihan R Guo J Ward RM Fu X Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation Breast Cancer Res 2011 13 R121 10.1186/bcr3067 22123186
Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, et al. Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers-role of estrogen receptor and HER2 reactivation. Breast Cancer Res. 2011;13:R121.22123186 10.1186/bcr3067
85. Schettini F Buono G Cardalesi C Desideri I De Placido S Del Mastro L Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going Cancer Treat Rev 2016 46 20 6 10.1016/j.ctrv.2016.03.012 27057657
Schettini F, Buono G, Cardalesi C, Desideri I, De Placido S, Del Mastro L. Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. Cancer Treat Rev. 2016;46:20–6.27057657 10.1016/j.ctrv.2016.03.012
86. O’Sullivan CC Suman VJ Goetz MP The emerging role of CDK4/6i in HER2-positive breast cancer Ther Adv Med Oncol 2019 11 1758835919887665 10.1177/1758835919887665 31832106
O’Sullivan CC, Suman VJ, Goetz MP. The emerging role of CDK4/6i in HER2-positive breast cancer. Ther Adv Med Oncol. 2019;11:1758835919887665.31832106 10.1177/1758835919887665
87. Finn RS Dering J Conklin D Kalous O Cohen DJ Desai AJ PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro Breast Cancer Res 2009 11 R77 10.1186/bcr2419 19874578
Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77.19874578 10.1186/bcr2419
88. Sinclair WD Cui X The Effects of HER2 on CDK4/6 activity in breast cancer Clin Breast Cancer 2022 22 e278 e85 10.1016/j.clbc.2021.08.007 34607757
Sinclair WD, Cui X. The Effects of HER2 on CDK4/6 activity in breast cancer. Clin Breast Cancer. 2022;22:e278–e85.34607757 10.1016/j.clbc.2021.08.007
89. Goel S Wang Q Watt AC Tolaney SM Dillon DA Li W Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors Cancer Cell 2016 29 255 69 10.1016/j.ccell.2016.02.006 26977878
Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors. Cancer Cell. 2016;29:255–69.26977878 10.1016/j.ccell.2016.02.006
90. Tolaney SM Wardley AM Zambelli S Hilton JF Troso-Sandoval TA Ricci F Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial Lancet Oncol 2020 21 763 75 10.1016/S1470-2045(20)30112-1 32353342
Tolaney SM, Wardley AM, Zambelli S, Hilton JF, Troso-Sandoval TA, Ricci F, et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial. Lancet Oncol. 2020;21:763–75.32353342 10.1016/S1470-2045(20)30112-1
91. Ciruelos E Villagrasa P Pascual T Oliveira M Pernas S Paré L Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial Clin Cancer Res 2020 26 5820 9 10.1158/1078-0432.CCR-20-0844 32938620
Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, et al. Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clin Cancer Res. 2020;26:5820–9.32938620 10.1158/1078-0432.CCR-20-0844
92. Yan M Niu L Lv H Zhang M Wang J Liu Z Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial Nat Commun 2023 14 6272 10.1038/s41467-023-41955-7 37805496
Yan M, Niu L, Lv H, Zhang M, Wang J, Liu Z, et al. Dalpiciclib and pyrotinib in women with HER2-positive advanced breast cancer: a single-arm phase II trial. Nat Commun. 2023;14:6272.37805496 10.1038/s41467-023-41955-7
93. Lin NU Gaspar LE Soffietti R Breast cancer in the central nervous system: multidisciplinary considerations and management Am Soc Clin Oncol Educ Book 2017 37 45 56 10.1200/EDBK_175338 28561683
Lin NU, Gaspar LE, Soffietti R. Breast cancer in the central nervous system: multidisciplinary considerations and management. Am Soc Clin Oncol Educ Book. 2017;37:45–56.28561683 10.1200/EDBK_175338
94. Raub TJ Wishart GN Kulanthaivel P Staton BA Ajamie RT Sawada GA Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft Drug Metab Dispos 2015 43 1360 71 10.1124/dmd.114.062745 26149830
Raub TJ, Wishart GN, Kulanthaivel P, Staton BA, Ajamie RT, Sawada GA, et al. Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an intracranial glioblastoma xenograft. Drug Metab Dispos. 2015;43:1360–71.26149830 10.1124/dmd.114.062745
95. Deng J Wang ES Jenkins RW Li S Dries R Yates K CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation Cancer Discov 2018 8 216 33 10.1158/2159-8290.CD-17-0915 29101163
Deng J, Wang ES, Jenkins RW, Li S, Dries R, Yates K, et al. CDK4/6 inhibition augments antitumor immunity by enhancing T-cell activation. Cancer Discov. 2018;8:216–33.29101163 10.1158/2159-8290.CD-17-0915
96. Kumar A Ramani V Bharti V de Lima Bellan D Saleh N Uzhachenko R Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses J Immunother Cancer 2023 11 e006019 10.1136/jitc-2022-006019 37230537
Kumar A, Ramani V, Bharti V, de Lima Bellan D, Saleh N, Uzhachenko R, et al. Dendritic cell therapy augments antitumor immunity triggered by CDK4/6 inhibition and immune checkpoint blockade by unleashing systemic CD4 T-cell responses. J Immunother Cancer. 2023;11:e006019.37230537 10.1136/jitc-2022-006019
97. Rugo HS Kabos P Beck JT Jerusalem G Wildiers H Sevillano E Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study NPJ Breast Cancer 2022 8 118 10.1038/s41523-022-00482-2 36335120
Rugo HS, Kabos P, Beck JT, Jerusalem G, Wildiers H, Sevillano E, et al. Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b study. NPJ Breast Cancer. 2022;8:118.36335120 10.1038/s41523-022-00482-2
98. Jerusalem G Prat A Salgado RF Reinisch M Saura C Ruiz Borrego M 92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8 Ann Oncol 2022 33 S165 S6 10.1016/j.annonc.2022.03.108
Jerusalem G, Prat A, Salgado RF, Reinisch M, Saura C, Ruiz Borrego M, et al. 92MO Neoadjuvant nivolumab (NIVO) + palbociclib (PALBO) + anastrozole (ANA) for estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer (BC): CheckMate 7A8. Ann Oncol. 2022;33:S165–S6.10.1016/j.annonc.2022.03.108
99. Herold CI Trippa L Li T Do K Bardia A Anderson L Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC) Cancer Res 2020 80 P3-14-03 P3-14-03 10.1158/1538-7445.SABCS19-P3-14-03
Herold CI, Trippa L, Li T, Do K, Bardia A, Anderson L, et al. Abstract P3-14-03: A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR+ MBC) and metastatic ovarian cancer (MOC). Cancer Res. 2020;80:P3-14-03–P3-14-03.10.1158/1538-7445.SABCS19-P3-14-03
100. Masuda J, Sakai H, Tsurutani J, Tanabe Y, Masuda N, Iwasa T, et al. Efficacy, safety, and biomarker analysis of nivolumab in combination with abemaciclib plus endocrine therapy in patients with HR-positive HER2-negative metastatic breast cancer: a phase II study (WJOG11418B NEWFLAME trial). J Immunother Cancer. 11 (2023).
101. Fassl A Geng Y Sicinski P CDK4 and CDK6 kinases: From basic science to cancer therapy Science 2022 375 eabc1495 10.1126/science.abc1495 35025636
Fassl A, Geng Y, Sicinski P. CDK4 and CDK6 kinases: From basic science to cancer therapy. Science. 2022;375:eabc1495.35025636 10.1126/science.abc1495
102. Yousuf M Alam M Shamsi A Khan P Hasan GM Rizwanul Haque QM Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: a review on therapeutic implications Int J Biol Macromol 2022 218 394 408 10.1016/j.ijbiomac.2022.07.156 35878668
Yousuf M, Alam M, Shamsi A, Khan P, Hasan GM, Rizwanul Haque QM, et al. Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: a review on therapeutic implications. Int J Biol Macromol. 2022;218:394–408.35878668 10.1016/j.ijbiomac.2022.07.156
103. Spring LM Zangardi ML Moy B Bardia A Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations Oncologist 2017 22 1039 48 10.1634/theoncologist.2017-0142 28706010
Spring LM, Zangardi ML, Moy B, Bardia A. Clinical management of potential toxicities and drug interactions related to cyclin-dependent kinase 4/6 inhibitors in breast cancer: practical considerations and recommendations. Oncologist. 2017;22:1039–48.28706010 10.1634/theoncologist.2017-0142
104. Wani K Patel K Dabak V Hepatotoxicity after CDK 4/6 inhibitor initiation in the treatment of hormone-positive metastatic breast cancer Cureus 2023 15 e40871 37363122
Wani K, Patel K, Dabak V. Hepatotoxicity after CDK 4/6 inhibitor initiation in the treatment of hormone-positive metastatic breast cancer. Cureus. 2023;15:e40871.37363122
105. Pavlovic D Niciforovic D Papic D Milojevic K Markovic M CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review Ther Adv Med Oncol 2023 15 17588359231205848 10.1177/17588359231205848 37841752
Pavlovic D, Niciforovic D, Papic D, Milojevic K, Markovic M. CDK4/6 inhibitors: basics, pros, and major cons in breast cancer treatment with specific regard to cardiotoxicity - a narrative review. Ther Adv Med Oncol. 2023;15:17588359231205848.37841752 10.1177/17588359231205848
